The SMA Trust held an evening reception at the Academy of Medical Sciences, on Tuesday 7th March. The aim of this event was to provide an update on the work of the SMA research Consortium with a view to thanking current supporters. A mix of major donors, scientists and research managers from other organisations attended, as well as our new Patron, Professor Dame Kay Davies.
The Consortium was founded on the principle that a comprehensive approach to SMA treatment is required, which takes into account the requirement for neuroprotective therapies throughout the
lifespan of the individual. The work started in January 2016 with the formation of 6 different groups at Universities across the UK.
The evening was centred around presentations by Professors Kevin Talbot and Tom Gillingwater on the advances made by the groups. These included the confirmation that UBA1, a molecule involved in protein degradation, is a target for SMA therapy and the discovery of defects in muscle and metabolism in SMA. To close, Freddie Sheffield and Octavia Woodward, who both have SMA Type 2, talked to the guests on what the Consortium’s research means to them.
The evening was seen as a great success and The SMA Trust is now looking at ways in which it could provide such updates in a more accessible way.